and in a phase 1 study achieved clinically significant body weight reductions over 12 weeks in people with obesity and without diabetes, according to Amgen. The drug was given as a subcutaneous ...

Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack. The Thousand Oaks, California-based drugmaker didn ...

Amgen’s mysterious obesity asset will remain a mystery for ... the candidate and doesn’t think the issue is related to the drug. The company didn't offer any other details about the hold.

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on ...

Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

Amgen said Tuesday that the Food and Drug Administration has ordered a hold on a study of the company’s early-stage obesity candidate, another potential setback in the company’s efforts to ...

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...

Investors were keenly interested to hear an update on Amgen’s obesity drug candidates, AMG-513 and MariTide. As noted above, the FDA has put AMG-513 on a clinical hold. Amgen says that it’s in ...

MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new ...

Coming up: Amgen is moving its obesity drug candidate into phase 3 in the first half of 2025. We now assume that this implies phase 3 data in late 2026 and a 2028 launch (previously assumed a 2027 ...